Clinical Trials

BioAge's $198M IPO Marks Major Shift Towards Innovative Obesity Drugs
Research & Development BioAge's $198M IPO Marks Major Shift Towards Innovative Obesity Drugs

BioAge Labs has recently garnered significant attention with its successful initial public offering (IPO), raising a formidable $198 million. Demonstrating the company's strategic pivot towards obesity drug research, this financial feat is particularly notable given the challenging environment for

How Will Lonza-Vertex Deal Transform Gene Therapy for SCD and Thalassemia?
Research & Development How Will Lonza-Vertex Deal Transform Gene Therapy for SCD and Thalassemia?

The long-term commercial supply agreement between Lonza and Vertex Pharmaceuticals marks a pivotal moment in the field of gene therapy, promising significant advancements for patients suffering from sickle cell disease (SCD) and beta-thalassemia. This collaboration focuses on the production of

How Will FDA's sIRB Mandate Transform Multisite Clinical Trials?
Research & Development How Will FDA's sIRB Mandate Transform Multisite Clinical Trials?

The clinical research landscape is on the cusp of a transformative shift with the U.S. Food and Drug Administration (FDA) poised to implement a groundbreaking regulation by May 2025. This regulation mandates the use of a single, centralized institutional review board (sIRB) for multisite trials,

Kaida BioPharma Enhances Social Media Presence to Combat Cancer
Research & Development Kaida BioPharma Enhances Social Media Presence to Combat Cancer

Kaida BioPharma, an emerging pharmaceutical company based in Fort Lauderdale, Florida, has announced the launch of its new corporate social media channels. This significant development aims to enhance the company’s presence across various platforms, including X, LinkedIn, and Facebook. By

Can GC Therapeutics' TFome Platform Revolutionize Cell Therapy?
Research & Development Can GC Therapeutics' TFome Platform Revolutionize Cell Therapy?

GC Therapeutics (GCTx), a biotech company founded in 2019, has captured the spotlight with its pioneering approach to cell therapy. With a mission centered on advanced induced pluripotent stem cell (iPSC)-based medicines, GCTx is driven by its innovative TFome platform. Bolstered by a successful

Ascendis Trials Shake Up the Market for Achondroplasia Treatments
Research & Development Ascendis Trials Shake Up the Market for Achondroplasia Treatments

The competitive landscape of pharmaceutical treatments for achondroplasia, a common cause of dwarfism, is experiencing a seismic shift, thanks to the recent clinical trial results from Ascendis Pharma. BioMarin Pharmaceutical, a long-time player in this niche market, finds itself under significant

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later